SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Status:
Terminated
Trial end date:
2018-09-07
Target enrollment:
Participant gender:
Summary
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to
be a safe strategy to cure severe sickle cell disease. However, due to a lack of suitable
donors, many patients cannot benefit from this strategy. Alternative donor sources are
desperately needed to fill this gap. Nearly all patients will have a haploidentical family
member who would be able to donate. The use of post transplantation cyclophosphamide has
greatly improved the outcome of haploidentical stem cell transplantation. The investigators
propose to combine this with alemtuzumab/TBI conditioning.